Study of Apolipoprotein E Polymorphism as a Biomarker in Coronary Artery Diseases

Authors

  • Saad M. El-Gendy prof. of Medical Bioch./Cancer Biolog
  • Yousef Aldebas
  • Sanaa O. Abdallah
  • Ahmed A. Sayed
  • Heba N. El-Sayed

Keywords:

Coronary artery diseases, apolipoprotein E, Atherosclerosis, triacylglycerol, HDL-c, LDL-c, Cholesterol

Abstract

This study aims to evaluate the role of apolipoprotein (apo) E gene mutation of all potentially atherogenic lipoproteins, as predictors of Coronary Heart Diseases (CHD) and its association with other biochemical changes such as; total cholesterol,TG, HDL-c, LDL-c, VLDL-c, in absence and presence of diabetes mellitus to reflect the presence of diabetes mellitus (DM). Results: This study was conducted on 45 individualscategorised into, Control group, Cardiac patients without DM (Group I) and Cardiac patients with DM (Group II). In our studied population, the mean levels of cholesterol, triglycerides and the ratio of LDL/HDL didn’t show any significant increase in group I compared to control group; whereas the mean levels of LDL and HDL showed significant increase compared to control group. The mean level of serum cholesterol, triglycerides, LDL, HDL and ratio of LDL/HDL showed significant increase in group II compared to control group.

The major common allele in the control group was E2, which has represented 53.3 %, E3 has represented 33%, while E4 has contributed 14 %, in addition, the major common allele in the group I was E3 that formed 50 % of group I sample, followed by E2 with 33% and tailed by E4 with a 16 % contribution. In contrast to group I, group II major common allele was E3, which has represented 53% of samples examined, whereas E2 and E4 have represented 23.3 % for each.

Conclusion: ApoE expression is considered a good criteria to recognize patients suffering from coronary heart disease. Carriers of E2, E3, and E4 differ in their binding affinity to cholesterol. Carriers of the E3, E4 alleles are slower to clear dietary fat from the blood, whereas carriers E2 has high affinity for cholesterol and shows a protective effect against cardiovascular disease. This study clearly concludes that people who have alleles E2/E2, E2/E4 may not suffer from coronary heart disease.

 

Author Biography

Saad M. El-Gendy, prof. of Medical Bioch./Cancer Biolog

prof. of Medical biochem, optometry dept., qassim University, KSA.

References

- Biggerstaff K.D. and Wooten J.S.: Understanding lipoproteins as transporters of cholesterol and other lipids. Advanced Physical Education.; 28: 105-106, 2004.

- Castelli W.P., Garrison R.J., Wilson P.W., Abbott R.D., Kalousidan S. and Kannel W.B.: Is good cholesterol always good. BMJ., 329: 471-472, 2004.

- Chia-Chen Liu, Takahisa Kanekiyo, Huaxi Xu and Guojun B.: Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nature Reviews Neurology, 9: 106-118, 2013.

- Cobble M.: Coronary heart disease in women. J Fam Pract., 63(2): 9-14, 2014.

- Constance C.: The good and the bad: what researchers have learned about dietary cholesterol, lipid management and cardiovascular disease risk since the Harvard Egg Study. Int J Clin Prasct Suppl., 163: 9-14, 2009.

- Eilertsen K.E., Mæhre H.K., Cludts K., Olsen J.O., Hoylaerts M.F.: Dietary enrichment of apolipoprotein E-deficient mice with extra virgin olive oil in combination with seal oil inhibits atherogenesis. Lipids Health Dis., 3: 10-41, 2011.

- Hallman D.M., Boerwinkle E. and Saha N.: A comparison of allele frequencies and effects in nine populations. Am. J. Hum. Genet., 45:793–802, 1991.

- Hixson J.E., and Vernier D.T.: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res., 31: 545–548, 1990.

- Hostage C.A, Choudhury K.R., Murali Doraiswamy P., Petrella J.R.: For the Alzheimer's Disease Neuroimaging Initiative. Mapping the effect of the apolipoprotein E genotype on 4-year atrophy rates in an alzheimer disease-related brain network. Radiology, 12:131041, 2013.?

- Galema-Boers J.M., Lenzen M.J., van Domburg R.T., Roeters van Lennep J., van Bruchem-van de Scheur G.G., Sijbrands E.J., Langendonk J.G.: Predicting non-adherence in patients with familial hypercholesterolemia. Eur J Clin Pharmacol., 2014.

- Jelinek M.V., Santamaria J.D., Best J.D., Thompson D.R., Tonkin A.M., Vale M.J.: Reversing social disadvantage in secondary prevention of coronary heart disease. Int J Cardiol.,171(3):346-50, 2014.

- June E.E., Terence S.D., Ghazala P., David M., Thompson, Kenneth E., Stewart and Berrit C.S.: Apolipoprotein E Polymorphism and Cardiovascular Disease: A HuGE Review. American Journal of Epidemiology, 155(6): 487-495, 2002.

- Jensen M.K., Rimm E.B., Furtado J.D., Sacks F.M.: Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease. J Am Heart Assoc., (2): 22-30, 2012.

- Kirsty G., Nigel J.P. and Dipak P.R.: The key role of apolipoprotein E in atherosclerosis. Journal of Molecular Medicine, 83 (5): 329-342, 2005.

- Kolovou GD, Panagiotakos DB, Kolovou V, Vasiliadis I, Giannakopoulou V, Diakoumakou O, Katsiki N, Mavrogeni S. Common Variants of Apolipoprotein E and Cholesteryl Ester Transport Protein Genes in Male Patients With Coronary Heart Disease and Variable Body Mass Index. , Angiology, 2014.?

- Koutsis G., Panas M., Giogkaraki E., Potagas C., Karadima G., Sfagos C. and Vassilopoulos D.: APOE E4 is associated with impaired verbal learning in patients with MS. Neurology, 68: 546-549, 2007.

- Krolewski A.S., Warram J.H., Valsania P., Martin B.C., Laffel L.M. and Christlieb A.R.: Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med., 90(2A): 56S-61S, 1991.

- Li Y.J., Hauser M.A., Scott W.K., Martin E.R., Booze M.W., Qin X.J, Walter J.W., Nance M.A., Hubble J.P., Koller W.C., Pahwa R., Stern M.B., Hiner B.C., Jankovic J., Goetz C.G., Small G.W., Mastaglia F., Haines J.L., Pericak V. M.A. and Vance J.M.: Apolipoprotein E controls the risk and age at onset of Parkinson disease, 62(11): 2005-2009, 2004.

- Maton and Anthea.: Human Biology and Health. Englewood Cliffs, New Jersey,USA: Prentice Hall. ISBN, 0-13-981176-1. 1993.

- Marco S.B., Kim M.F., Silvia G., Priori, Peter C., Caroline D., Ian G., Benct J., Karin S. and Michal T.: Cardiovascular diseases in women: a statement from the policy conference of the :European Heart Journal, 27(8): 994-1005, 2006.

- Mahley R.W. and Rall S.C.J.: Apolipoprotein E far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet., 1: 507–537, 2000.

- Middelhoff G., Augustin J., Klose G. and Greten H.: Lipid – protein interactions of human apolipoproteins structural aspects and models of lipoproteins (author's transl) 55(4):149-60, 1977.

- Moreno A., Francisco P. J., Carmen M., Purificación G., Pablo P.M., Rafael M., Cecilia B., Francisco F. and José L.M.: Dietary Fat on LDL Size Is Influenced by Apolipoprotein E Genotype in Healthy Subjects. J. Nutr., 134: 2517-2522, 2004.

- Mortensen E.L. and Peter H.: A gender difference in the association between APOE genotype and age- related cognitive decline. American Academy of Neurology 57:89-95, 2001.

- Ng D.S.: Diabetic dyslipidemia: from evolving pathophysiological insight to emerging therapeutic targets. Can J Diabetes, 37(5):319-26, 2013.

- Pamela M., Trey S., Judy L., Friz and Raja P.: Genetics and visual attention: Selective deficits in healthy adult carriers of the «4 allele of the apolipoprotein E gene. Proc Natl Acad Sci U S A., 97(21):11661-11666, 2000.

- Raffai R.L., Dong L.M., Farese R.V. and Weisgraber K.H.: Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. Proc Natl Acad Sci U S A., 98(20):11587-11591, 2001.

- Richardson J.R., Roy A., Shalat S.L., von Stein R.T., Hossain M.M., Buckley B., Gearing M., Levey A.I., German D.C..: Elevated serum pesticide levels and risk for Alzheimer disease. JAMA Neurol., 71(3): 284-290, 2014.

- Saito H., Dhanasekaran P., Baldwin F., Weisgraber K.H., Lund-Katz S., Phillips M.C.: Lipid binding-induced conformational change in human apolipoprotein E. Evidence for two lipid-bound states on spherical particles. J. Biol. Chem.; 276:40949–40954, 2001.

- Siest G., Pillot T. and Régis-Bailly A.: Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin. Chem., 41: 1068–1086, 2000.

- Song Y., Stampfer M.J. and Liu S.: Meta-Analysis: Apolipoprotein E Genotypes and Risk for Coronary Heart Disease. Ann Intern Med., 141(2): 137 – 147, 2004.

- Stengard E.A. and Myers G.L.: Lipids, apolipoproteins and lipoproteins. In: Burtis C.A. and Ashwood, E.R. (eds): Tietz fundamentals of clinical chemistry, 4th edition. Philadelphia, Saunders co. 375-401, 1996.

- Tammi A., Rönnemaa T., Rask-Nissilä L., Miettinen T.A., Gylling H., Valsta L., Viikari J., Välimäki I. and Simell O.: Apolipoprotein E Phenotype Regulates Cholesterol Absorption in Healthy 13-Month-Old Children-The STRIP Study. Pediatr Res,. 50:688–691, 2001.

- Tonolo G.: The prevention of type II diabetes-life style changes or pharmacotherapy. A challenge for the 21st century. Diabetes Research and Clinical Practice, 59 (3):165-180, 2006.

- Ward H., Mitrou P.N., Bowman R., Luben R., Wareham N.J., Khaw K.T.: Bingham SAPOE genotype, lipids, and coronary heart disease risk: a prospective population study. Arch Intern Med., 169 (15), 1424-9, 2009.

- Wu J.H., Lo S., Wen M. and Kao J.: Characterization of apolipoprotein E genetic variations in Taiwanese: association with coronary heart disease and plasma lipid levels. Hum Biol., 74(1): 25-31, 2002.

- Xuemei H., Peter C., Chen B.S. and Charles P.: APOE- 2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology, 62: 2198-2202, 2004.

Downloads

Published

2014-04-14

How to Cite

El-Gendy, S. M., Aldebas, Y., Abdallah, S. O., Sayed, A. A., & El-Sayed, H. N. (2014). Study of Apolipoprotein E Polymorphism as a Biomarker in Coronary Artery Diseases. Asian Journal of Applied Sciences, 2(2). Retrieved from https://ajouronline.com/index.php/AJAS/article/view/1028

Issue

Vol. 2 No. 2 (2014): April 2014

Section

Articles

License

  • Papers must be submitted on the understanding that they have not been published elsewhere (except in the form of an abstract or as part of a published lecture, review, or thesis) and are not currently under consideration by another journal published by any other publisher.
  • It is also the authors responsibility to ensure that the articles emanating from a particular source are submitted with the necessary approval.
  • The authors warrant that the paper is original and that he/she is the author of the paper, except for material that is clearly identified as to its original source, with permission notices from the copyright owners where required.
  • The authors ensure that all the references carefully and they are accurate in the text as well as in the list of references (and vice versa).
  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Attribution-NonCommercial 4.0 International that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
  • The journal/publisher is not responsible for subsequent uses of the work. It is the author's responsibility to bring an infringement action if so desired by the author.